Survival time to Implanon discontinuation and its predictors among a cohort of Implanon users who enrolled in public hospitals of southern Ethiopia, 2021: a retrospective cohort study.
Ethiopia
Implanon discontinuation
Predictors
Survival time
Journal
Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826
Informations de publication
Date de publication:
23 Mar 2022
23 Mar 2022
Historique:
received:
20
09
2021
accepted:
18
03
2022
entrez:
24
3
2022
pubmed:
25
3
2022
medline:
25
3
2022
Statut:
epublish
Résumé
Pieces of evidence strongly indicate that providing high-quality family planning services is accompanied by an increase in contraceptive uptake and a decrease in contraception discontinuation. Contraceptive, especially Implanon discontinuation is a global issue that could be linked to a summary outcome indicator of poor family planning service quality. Although Implanon is becoming more popular among Ethiopian contraceptive users, little is known regarding the survival and predictors of discontinuation. The study aimed at exploring the survival and predictors of Implanon discontinuation among women enrolled in family planning units of Public hospitals in southern Ethiopia, 2021. A hospital-based retrospective cohort study was conducted among Implanon users who enrolled in family planning units of Public Hospitals. Five years of medical records, from January 1, 2016, to December 30, 2020, were reviewed. A total of 502 women were selected by using a random sampling technique. A standardized abstraction tool was used to collect data from medical records and registration books. The data were entered into Epidata Version 3.1 and then exported to STATA 14 for analysis. The median was calculated in the case of survival time. Across covariates, the Kaplan Meier survival curve was used to estimate time to Implanon discontinuation. To identify statistically significant predictors of Implanon discontinuation, a multivariable Cox proportional hazard model was fitted. The incidence rate of Implanon discontinuation was 1.87(95% CI = 1.63, 2.15) per 100 person-months of observation. The overall estimated survival probability at the end of 24 and 36 months was 67.4% (95%CI, 62.5, 71.8) and 25.9% (95%CI, 18.4, 34.1) months respectively. Residence [AHR = 1.50; 95%CI: 1.09, 2.08], parity [AHR = 2.02; 95%CI: 1.65, 3.67], pre-insertion counselling [AHR = 2.41; 95%CI: 1.72, 3.70], experiencing heavy vaginal bleeding [AHR = 3.91; 95%CI: 2.67, 5.32], post-insertion follow up [AHR = 3.15; 95%CI:2.11, 4.75] were identified as a significant predictors of Implanon discontinuation. The risk Implanon of discontinuation was high, especially at 24 and 36 months. In family planning service delivery points, health care providers should pay special attention to clients who live in rural areas and do not have children. In addition, health care providers should provide pre-insertion counseling and post-insertion follow-up that focus on potential side effects. Finally, family planning units need to engage in early side effect management and reassurance to mitigate discontinuation.
Sections du résumé
BACKGROUND
BACKGROUND
Pieces of evidence strongly indicate that providing high-quality family planning services is accompanied by an increase in contraceptive uptake and a decrease in contraception discontinuation. Contraceptive, especially Implanon discontinuation is a global issue that could be linked to a summary outcome indicator of poor family planning service quality. Although Implanon is becoming more popular among Ethiopian contraceptive users, little is known regarding the survival and predictors of discontinuation. The study aimed at exploring the survival and predictors of Implanon discontinuation among women enrolled in family planning units of Public hospitals in southern Ethiopia, 2021.
METHODS
METHODS
A hospital-based retrospective cohort study was conducted among Implanon users who enrolled in family planning units of Public Hospitals. Five years of medical records, from January 1, 2016, to December 30, 2020, were reviewed. A total of 502 women were selected by using a random sampling technique. A standardized abstraction tool was used to collect data from medical records and registration books. The data were entered into Epidata Version 3.1 and then exported to STATA 14 for analysis. The median was calculated in the case of survival time. Across covariates, the Kaplan Meier survival curve was used to estimate time to Implanon discontinuation. To identify statistically significant predictors of Implanon discontinuation, a multivariable Cox proportional hazard model was fitted.
RESULTS
RESULTS
The incidence rate of Implanon discontinuation was 1.87(95% CI = 1.63, 2.15) per 100 person-months of observation. The overall estimated survival probability at the end of 24 and 36 months was 67.4% (95%CI, 62.5, 71.8) and 25.9% (95%CI, 18.4, 34.1) months respectively. Residence [AHR = 1.50; 95%CI: 1.09, 2.08], parity [AHR = 2.02; 95%CI: 1.65, 3.67], pre-insertion counselling [AHR = 2.41; 95%CI: 1.72, 3.70], experiencing heavy vaginal bleeding [AHR = 3.91; 95%CI: 2.67, 5.32], post-insertion follow up [AHR = 3.15; 95%CI:2.11, 4.75] were identified as a significant predictors of Implanon discontinuation.
CONCLUSION
CONCLUSIONS
The risk Implanon of discontinuation was high, especially at 24 and 36 months. In family planning service delivery points, health care providers should pay special attention to clients who live in rural areas and do not have children. In addition, health care providers should provide pre-insertion counseling and post-insertion follow-up that focus on potential side effects. Finally, family planning units need to engage in early side effect management and reassurance to mitigate discontinuation.
Identifiants
pubmed: 35321741
doi: 10.1186/s13690-022-00859-6
pii: 10.1186/s13690-022-00859-6
pmc: PMC8941807
doi:
Types de publication
Journal Article
Langues
eng
Pagination
89Informations de copyright
© 2022. The Author(s).
Références
Contraception. 1995 Mar;51(3):155-65
pubmed: 7621684
BMC Res Notes. 2019 Jan 7;12(1):8
pubmed: 30616681
Stud Fam Plann. 2002 Jun;33(2):127-40
pubmed: 12132634
Open Access J Contracept. 2015 Jan 29;6:13-19
pubmed: 29386920
Int Fam Plan Perspect. 2003 Jun;29(2):76-83
pubmed: 12783771
PLoS One. 2020 Nov 5;15(11):e0241605
pubmed: 33151972
Niger J Med. 2011 Oct-Dec;20(4):448-50
pubmed: 22288321
Glob Health Sci Pract. 2013 Jul 26;1(2):180-92
pubmed: 25276531
Contraception. 2011 Oct;84(4):413-7
pubmed: 21920198
Gates Open Res. 2019 May 2;3:1453
pubmed: 32140663
Sci Rep. 2021 May 24;11(1):10819
pubmed: 34031521
BMC Womens Health. 2018 Feb 05;18(1):35
pubmed: 29402320
Hum Reprod. 1999 Apr;14(4):976-81
pubmed: 10221230
Int J Reprod Med. 2018 Jan 21;2018:3597487
pubmed: 29796392
J Health Popul Nutr. 2014 Mar;32(1):142-8
pubmed: 24847603
Afr J Reprod Health. 2020 Jun;24(2):48-63
pubmed: 34077091
Semin Reprod Med. 2010 Mar;28(2):110-7
pubmed: 20352560
BMJ Sex Reprod Health. 2018 Jun 28;:
pubmed: 29954878
BMC Womens Health. 2018 Nov 20;18(1):189
pubmed: 30453931
Stud Fam Plann. 2015 Dec;46(4):369-86
pubmed: 26643488
Int J Gynaecol Obstet. 2013 Nov;123 Suppl 1:e29-32
pubmed: 24035007
Fertil Steril. 1998 Apr;69(4):714-21
pubmed: 9548163
Stud Fam Plann. 2010 Dec;41(4):241-50
pubmed: 21465725
PLoS One. 2020 May 11;15(5):e0232582
pubmed: 32392216
Obstet Gynecol. 2013 Dec;122(6):1214-21
pubmed: 24201685
Fam Med. 2013 Nov-Dec;45(10):701-7
pubmed: 24347187
Contraception. 2010 Jan;81(1):22-9
pubmed: 20004269